Monday, February 10, 2025

South Korea Enhances Access to New Medicines via PEE Pricing

Similar articles

South Korea has witnessed a substantial rise in the availability of new pharmaceuticals since the implementation of the Pharmaco-Economic Evaluation Exemption (PEE) system, signaling a pivotal shift in the nation’s drug pricing landscape.

Table of Contents

Subscribe Weekly Market Access News

* indicates required

Surge in New Drug Listings

Between 2015 and 2022, the PEE system facilitated the introduction of 30 new drugs, with the number doubling in 2022 alone. This increase reflects enhanced pathways for innovative therapies to reach patients swiftly, addressing critical health needs more effectively than before.

Pricing Strategy and Budget Impact

Analysis reveals a significant negative correlation between the ‘KOR/A7 lowest’ pricing variable and the budget impact, suggesting that drugs exerting higher financial demands tend to be priced lower relative to the lowest prices in the A7 countries. This trend underscores the delicate balance policymakers must maintain between ensuring affordability and fostering pharmaceutical innovation.

Key inferences from the study include:

  • Higher budget impact prompts lower pricing of new drugs compared to regional benchmarks.
  • The PEE system’s flexibility may encourage pharmaceutical companies to prioritize cost-effective drug development.

As a result, patient access has significantly improved, but the escalating costs of pharmaceuticals pose ongoing challenges for healthcare budgets. The study emphasizes the necessity for continuous monitoring and potential policy refinements to navigate this complex landscape effectively.

Balancing cost containment with equitable access remains a central concern. Policymakers might consider developing tiered risk-sharing agreements based on drug classifications or therapeutic impacts to achieve sustainable healthcare financing while ensuring patients benefit from cutting-edge treatments.

Strategic adjustments and robust oversight are essential to sustain the progress made under the PEE system. By refining pricing models and enhancing economic evaluations, South Korea can better manage pharmaceutical expenditures without compromising the accessibility of vital new therapies.

Source

You can follow our news on our Telegram, LinkedIn and Youtube accounts.


This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article